Tourmaline bio presents phase 2 tranquility study design at american society of preventive cardiology (aspc) congress 2024

Phase 2 tranquility trial is evaluating the high-sensitivity c-reactive protein (hs-crp)-lowering effect, safety, tolerability, and pharmacokinetics (pk) of quarterly and monthly subcutaneous administration of tour006 in patients with chronic kidney disease and elevated hs-crp — dosing regimens are informed by six previous phase 1 and phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as pk/pd modeling — topline data is expected first half of 2025 — data from phase 2 tranquility trial have the potential to advance tour006 toward phase 3 readiness for atherosclerotic cardiovascular disease (ascvd) and other cardiovascular diseases. new york, aug. 02, 2024 (globe newswire) -- tourmaline bio, inc. (tourmaline) (nasdaq: trml), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today presented a poster at the american society of preventive cardiology (aspc) congress in salt lake city, utah, detailing the rationale and design of the company's tranquility phase 2 study examining the potential of its lead candidate, tour006, to reduce high-sensitivity c-reactive protein (hs-crp), a key biomarker of residual inflammatory cardiovascular risk, in patients with chronic kidney disease (ckd) and elevated hs-crp.
ASPC Ratings Summary
ASPC Quant Ranking